Science Corp. closes a $230M round to bring PRIMA to market

Science Corporation/PRIMA retinal implant

Science closed a $230 million Series C with existing investors including Khosla Ventures, Lightspeed, Y Combinator, IQT and Quiet Capital, bringing total funding to approximately $490 million since 2021. The capital funds commercialisation of PRIMA, the light-powered retinal implant, and expansion of clinical trials for geographic atrophy and other retinal diseases.

• $230M Series C from existing investors (Khosla, Lightspeed, Y Combinator, IQT, Quiet Capital) brings total funding to ~$490M.
• Funds commercialise PRIMA retinal implant and expand trials for geographic atrophy, Stargardt disease, and retinitis pigmentosa.
• Also advances biohybrid neural interfaces, vessel perfusion platform, MEMS foundry and broader BCI ecosystem.